All In Biotech

Drug Trial Radar · NCT01520818

Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With Diabetes

A Multinational, Randomised, Open-labelled, Parallel Group Four Months Comparison of Twice Daily Biphasic Human Insulin 30 and Thrice Daily Biphasic Insulin Aspart 50 and 70 in Subjects With Type 1 or Type 2 Diabetes

Last checked: Nov 20, 2026Latest source record: Jan 4, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 666 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

666

Actual

Start

Mar 2000

Primary completion

Apr 2001

Study completion Apr 2001

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jan 30, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted in Europe. The aim of this trial is to compare the glycaemic control of biphasic insulin aspart (BIAsp) 70 and/or BIAsp 50 with biphasic human insulin (BHI) 30 treatment.

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2

Interventions

  • biphasic insulin aspart 50Drug

    Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being obese with a body mass index (BMI) exceeding 30 kg/m\^2 will receive BIAsp 50

  • biphasic insulin aspart 70Drug

    Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being lean and overweight with a body mass index (BMI) of maximum 30 kg/m\^2 will receive BIAsp 70

  • biphasic human insulin 30Drug

    Administered subcutaneously (s.c., under the skin), twice a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HbA1c (glycosylated haemoglobin A1c)

Locations

77 sites in 5 countries. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Aalst, Belgium

  • Novo Nordisk Investigational Site

    Brussels, Belgium

  • Novo Nordisk Investigational Site

    Brussels, Belgium

  • Novo Nordisk Investigational Site

    Edegem, Belgium

  • Novo Nordisk Investigational Site

    Genk, Belgium

  • Novo Nordisk Investigational Site

    Jumet, Belgium

  • Novo Nordisk Investigational Site

    Liège, Belgium

  • Novo Nordisk Investigational Site

    Amiens, France

  • Novo Nordisk Investigational Site

    Avignon, France

  • Novo Nordisk Investigational Site

    Bagnols-sur-Cèze, France

  • Novo Nordisk Investigational Site

    Bordeaux, France

  • Novo Nordisk Investigational Site

    Caen, France

  • Novo Nordisk Investigational Site

    Colmar, France

  • Novo Nordisk Investigational Site

    Dijon, France

  • Novo Nordisk Investigational Site

    Dommartin-lès-Toul, France

  • Novo Nordisk Investigational Site

    Grenoble, France

  • Novo Nordisk Investigational Site

    La Rochelle, France

  • Novo Nordisk Investigational Site

    Le Creusot, France

  • Novo Nordisk Investigational Site

    Lorient, France

  • Novo Nordisk Investigational Site

    Lyon, France

  • Novo Nordisk Investigational Site

    Mâcon, France

  • Novo Nordisk Investigational Site

    Marseille, France

  • Novo Nordisk Investigational Site

    Nanterre, France

  • Novo Nordisk Investigational Site

    Narbonne, France

  • Novo Nordisk Investigational Site

    Nevers, France

  • Novo Nordisk Investigational Site

    Nîmes, France

  • Novo Nordisk Investigational Site

    Orléans, France

  • Novo Nordisk Investigational Site

    Paris, France

  • Novo Nordisk Investigational Site

    Paris, France

  • Novo Nordisk Investigational Site

    Reims, France

  • Novo Nordisk Investigational Site

    Roubaix, France

  • Novo Nordisk Investigational Site

    Saint-Etienne, France

  • Novo Nordisk Investigational Site

    Strasbourg, France

  • Novo Nordisk Investigational Site

    Toulouse, France

  • Novo Nordisk Investigational Site

    Dublin, Ireland

  • Novo Nordisk Investigational Site

    Dublin, Ireland

  • Novo Nordisk Investigational Site

    Dublin, Ireland

  • Novo Nordisk Investigational Site

    's-Hertogenbosch, Netherlands

  • Novo Nordisk Investigational Site

    Alkmaar, Netherlands

  • Novo Nordisk Investigational Site

    Amersfoort, Netherlands

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.